Hadassah

Hadassah Researchers Identify Connection Between National Killer Cell and Cirrhosis

Tuesday, Mar 19 2013

Researchers at the Hadassah University Medical Center have discovered that over expression of an immune system Natural Killer (NK) cell called Neuroligin 4 can trigger cirrhosis of the liver by preventing the body from combating scarring. The Hadassah study compared blood samples from dozens of patients with cirrhosis to those of a healthy control group. "In their healthy form, the Neuroligin cells kill the scar-tissue cells," reports Prof. Rifaat Safadi, head of Hadassah's Liver Unit and this study. In the over expression scenario, he explains, "a mechanism is put into operation that keeps the cells from doing their unscarring work."

Several years ago, the same research team found that intact NK cells are good for the liver and prevent cirrhosis. The finding was published in the February 2006 issue of The Journal of Hepatology and also reported by a group of researchers at the National Institutes of Health in the United States. Next, Hadassah's researchers plan to investigate whether mutations of Neuroligin 4 also increase the risk of cirrhosis.

Hadasit, Hadassah's Technology Transfer Company, has already patented Neuroligin 4 in hopes of using it to develop treatments to fend off liver disease.


Read the story in Haaretz here>>

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Aug 16 2017

Gazan Boy Walks for First Time at Hadassah

Unable to stand on his feet, suffering from severe respiratory distress, a four-year-old boy from Gaza gained the ability to walk once Hadassah Hospital surgeons identified and removed a large tumor lodged in his chest.

READ MORE ›
alt_text

Wednesday, Aug 16 2017

Hadassah Hosts Health Innovation Conference

Over one hundred doctors, researchers, and entrepreneurs gathered at Hadassah Hospital Ein Kerem this summer to discuss how to advance the quality of patient care with computational power.

READ MORE ›
alt_text

Monday, Aug 14 2017

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

READ MORE ›
alt_text

Thursday, Aug 3 2017

Mystery of Devastating Pediatric Disease Solved by Hadassah Team

A genetic mutation causing a rare and devastating pediatric neurological disease that has puzzled medical centers around the world has been identified at the Hadassah Medical Organization by Prof. Orly Elpeleg, head of Hadassah's Department of Genetics and Metabolic Diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More